Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.40 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6942693 | 0.88 | LDHA (0.54) | LDHAMMP13L3MBTL1PPARGPPARA | |
| SCHEMBL3776724 | 0.88 | LDHA (0.54) | LDHAMMP13L3MBTL1PPARGPPARA | |
| SCHEMBL20422635 | 0.88 | ESR1 (0.49) | MMP13ADORA1ITGA4ITGB7REN | |
| SCHEMBL20422634 | 0.88 | ESR1 (0.49) | MMP13ADORA1ITGA4ITGB7REN | |
| SCHEMBL23279486 | 0.87 | MEN1 (0.41) | MMP13ADORA1L3MBTL1ITGA4ITGB7 | |
| SCHEMBL3777215 | 0.87 | LDHA (0.46) | LDHAMMP13ADORA1L3MBTL1HTT | |
| SCHEMBL7906205 | 0.87 | ADORA1 (0.44) | MMP13ADORA1ITGA4ITGB7REN | |
| SCHEMBL8362441 | 0.87 | ADORA1 (0.51) | MMP13ADORA1ITGA4ITGB7PPARG | |
| SCHEMBL8362444 | 0.87 | ADORA1 (0.51) | MMP13ADORA1ITGA4ITGB7PPARG | |
| SCHEMBL6992860 | 0.87 | ADORA1 (0.41) | MMP13ADORA1ITGA4ITGB7REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317697-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| EP-2167609-A1 | RENIN INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009096996-A1 | RENIN INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317697-A1 | Renin Inhibitors | REN, ACE, SERPINB1 | LDHA 843/4885MMP13 514/4885ADORA1 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.